A Phase 1 interventional study of Pregabalin 150mg and Pregabalin 300mg in Healthy, sponsored by GL Pharm Tech Corporation. Completed. Open to male participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-12-30.
Sponsored by GL Pharm Tech Corporation · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this clinical trial is to compare the pharmacokinetic characteristics of GLA5PR GLARS tablet 150mg and Lyrica Capsule 75mg.
GLA5PR GLARS tablet 150mg is a New Formulation which is made by GL Pharm Tech.
GLARS(Geometrically Long Absorption Regulated System) is New Solution to Sustained Absorption by Extending the Absorption Site.
To overcome the shortcomings of the currently existing sustained release drug delivery technologies the investigators have recently developed a novel drug delivery system to enable a drug to be dissolved irrespective of the surrounding environment and further absorbed up to colon. The investigators coined this "Geometrically Long Absorption Regulated System(GLARS)".
Basically, this system is a triple-layered tablet, comprised of upper and lower layers that swell and draw a sufficient amount of water, plus a highly water - soluble middle layer that rapidly draw water into the tablet core simultaneously.
The water drawn into the tablet (about 3 to 4 times the weight of the tablet itself) functions as an additional media which enables additional and later drug release out of the dosage form. This serves to overcome the shortage of surrounding media that has been reported to be one of the key reasons for mal-absorption of a drug in colon.
As the middle layer induces a rapid water draw into the tablet core, the penetrated water also diffuses to the upper and lower layers, which makes the tablet to rapidly swell and controls drug release.
At virtually the same time, the swollen upper and lower layers form to surround a lateral side of the middle layer, which can, in turn, further control drug release.
This relatively rigid swollen matrix structure makes drug release not affected by surrounding mechanical flux, which can provide relatively consistent in vivo drug release irrespective of degree of gastrointestinal motility.
GL Pharm Tech Corporation is the lead sponsor of 16 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day, after meal)
Drug: Pregabalin 150mg
GLA5PR GLARS-NF1 tablet 300mg/day(Pregabalin 300mg once a day, after meal)
Drug: Pregabalin 300mg
GLA5PR GLARS-NF1 tablet 450mg/day(Pregabalin 150mg 1 tablet and Pregabalin 300mg 1 tablet, 1 times a day, after meal)
Drug: Pregabalin 150mg · Drug: Pregabalin 300mg
GLA5PR GLARS-NF1 tablet 600mg/day(Pregabalin 300mg, 2 tablets 1 times a day, after meal)
Drug: Pregabalin 300mg
GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day)
Also known as: GLA5PR GLARS-NF1 tablet 150mg
GLA5PR GLARS-NF1 tablet 300mg/day(Pregabalin 300mg once a day)
Also known as: GLA5PR GLARS-NF1 tablet 300mg
AUClast
Pharmacokinetic of Pregabalin
Time frame: 36hrs
Cmax
Pharmacokinetic of Pregabalin
Time frame: 36hrs
AUCinf
Pharmacokinetic of Pregabalin
Time frame: 36hrs
Tmax
Pharmacokinetic of Pregabalin
Time frame: 36hrs
t1/2
Pharmacokinetic of Pregabalin
Time frame: 36hrs
CL/F
Pharmacokinetic of Pregabalin
Time frame: 36hrs
Vd/F
Pharmacokinetic of Pregabalin
Time frame: 36hrs
No study locations are listed for this record.
The record gives a start of Oct 2014, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
GL Pharm Tech Corporation